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Abstract Mannan-binding lectin (MBL)-associated plasma
protein (MAp19) is an alternatively spliced form of MBL-
associated serine protease-2, a component of a complement
activation cascade. We observed that MAp19 is excreted in
human urine. Interestingly, the amount of MAp19 was higher in
urine of renal cell carcinoma patients than healthy people.
Pretreatment of urine dialysate with 50 mM EDTA increased the
recovery of MAp19, suggesting that MAp19 is a calcium-binding
protein. The recombinant MAp19 showed a strong inhibition of
calcium oxalate crystal growth in vitro in a concentration-
dependent manner. Thus, we conclude that MAp19 plays a role in
the inhibition of calcium oxalate renal stone formation.
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1. Introduction
Nephrolithiasis is a common disorder, and calcium oxalate
is the most common crystalline component of human renal
stones [1]. The nucleation and growth of calcium oxalate or
phosphate occur because urine in normal people is supersatu-
rated with these salts. However, the fraction of people who
form severe renal stones is relatively small. One reason why
urine supersaturation does not lead to stone formation and
nephrolithiasis is that urine contains inhibitors of crystalliza-
tion of calcium oxalate. Inhibitory proteins found in urine
include nephrocalcin [2,3], Tamm-Horsfall protein [4], uro-
pontin/osteopontin [5,6], crystal matrix protein (F prothrom-
bin fragment) [7], and uronic rich-acid protein [8]. Most of
these molecules are anionic with many acidic amino acid res-
idues, and appear to exert their e¡ects by binding to the sur-
face of calcium oxalate [9]. Although a Ca2-binding property
is important for their inhibitory function, the speci¢c struc-
tural motifs that favor crystal binding and inhibition are not
yet known. Some of the urinary inhibitor proteins are made
by renal epithelial cells, whereas others gain access to the
urine by glomerular ¢ltration.
Mannan-binding lectin (MBL) binds to many pathogens via
surface carbohydrates and induces cell lysis via complement
activation [10,11]. This MBL-induced activation of the com-
plement cascade was shown to occur via MBL-associated ser-
ine protease-1 (MASP-1), which consumes C2 and C3, and
has been proposed as the third pathway of complement acti-
vation [12^15]. MBL is related to the complement C1 sub-
component, C1q, and MASP-1 is similar to C1r and C1s
[11]. A second form of MBL-associated serine protease-2
(MASP-2) was also identi¢ed, which shows sequence homol-
ogy with previously reported MASP (MASP-1) and two C1q-
associated serine proteases, C1r and C1s [16]. Similarly to
MASP-1, MASP-2 is composed of an N-terminal C1r/C1s-
like domain, followed by an epidermal growth factor
(EGF)-like domain, a second C1r/C1s-like domain, two com-
plement control protein (CCP) domains, and a serine protease
domain [16]. Upon activation, it is cleaved into two disul¢de-
linked chains, an N-terminal 52 kDa polypeptide chain com-
posed of the ¢rst ¢ve domains and a C-terminal catalytically
active 31 kDa polypeptide chain [16,17]. Recently, the alter-
natively spliced form of MASP-2, MBL-associated plasma
protein (MAp19), was found to be associated with MASP-1
in plasma. It consists of the ¢rst two domains of MASP-2
with four di¡erent C-terminal amino acids [18]. MAp19 is
also shown to be the major translational product of the
MASP-2 gene in plasma although it is enzymatically in-
active as it lacks the serine protease domain. This result im-
plies that there may be some unknown roles of this protein
in addition to as a component of the MBL-MASP complex
[17].
Although several urinary inhibitors were identi¢ed, there is
a report suggesting the existence of other unknown proteins in
urine with strong inhibitory action of stone formation [19].
Therefore, we attempted to ¢nd a novel inhibitor of renal
stone formation in urine. Since nephrocalcin is excreted
more in urine of renal cell carcinoma patients [20,21], we
screened urine proteins from both patients with renal cell
carcinoma and normal adults.
2. Materials and methods
2.1. Materials
Diethylaminoethyl-cellulose (DEAE-Sephacell) was purchased from
Pharmacia. [14C]Oxalic acid was obtained from New England Nuclear
(NEN) Du Pont Co. Urine specimens were collected from patients
with renal cell carcinoma and normal adults. pET-21a plasmid was
from Novagen and Ni-NTA a⁄nity resin was from Qiagen. Hybond
membrane and ECL kit containing anti-rabbit IgG conjugated with
horseradish peroxidase (HRP) were purchased from Amersham. All
other chemicals were the highest grade available.
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2.2. Partial puri¢cation of MAp19
One liter of the collected urine was dialyzed against 12 l of deion-
ized water for 24 h at 4‡C with two changes. The dialysate was
adjusted to 50 mM NaCl, Tris-HCl, pH 7.3, and then mixed with 1/
10 volume of DEAE-cellulose preequilibrated with 50 mM Tris-HCl,
pH 7.3, 50 mM NaCl. The suspension was stirred for 30 min at room
temperature. After the resin had settled down, it was ¢ltered through
a glass wool ¢ber in the column. The DEAE-cellulose resin was
washed with a 50 mM Tris-HCl bu¡er, pH 7.3, containing 50 mM
NaCl to remove non-speci¢cally bound proteins. The proteins were
eluted using 180 mM NaCl, 50 mM Tris-HCl, a bu¡er, pH 7.3. For
EDTA treatment of urine samples, the dialysate was ¢rst adjusted to
50 mM EDTA, pH 8.0, and incubated for 24 h at 4‡C. After this
EDTA treatment, these dialysates were subjected to DEAE-cellulose
chromatography as above. The eluates were pooled and dialyzed
against 4 l of deionized water and lyophilized. Protein concentration
was determined by the Lowry method (Bio-Rad) using bovine serum
albumin as a standard.
2.3. SDS-polyacrylamide gel electrophoresis and peptide sequencing
The partially puri¢ed MAp19 was separated on 15% SDS-polyacryl-
amide gel and stained with Coomassie blue. After destaining, the
MAp19 band was excised. The peptides were eluted from the gel after
in situ tryptic digestion, and separated by HPLC. The amino acid
sequencing was performed using Applied Biosystems Division Precise
Protein/Peptide Sequencer. The resulting sequences were searched via
the BLAST Network Server.
2.4. Preparation of polyclonal antibody against MAp19
Peptide (LASPGFPGEYAND QER) was synthesized and coupled
to keyhole limpet hemocyanin using a bifunctional coupling reagent,
glutaraldehyde. New Zealand White rabbits were initially immunized
with 1 mg of peptide conjugate in 50% (v/v) Freund’s complete ad-
juvant (FCA). Five weeks after immunization, the rabbits were
boosted with 1 mg of peptide conjugate. The animals were bled
7 weeks after the initial immunization. Serum was collected by cen-
trifugation after clotting, and MAp19 antibody was puri¢ed from this
serum by ammonium sulfate precipitation and an antigen-bound
a⁄nity column.
2.5. Immunoblotting
Samples were separated by 15% SDS-PAGE and transferred elec-
trophoretically to Hybond nitrocellulose membrane (Amersham Co.)
at 400 mA for 3 h. The membrane was blocked with 5% skim milk,
and incubated with anti-MAp19 antibody. After washing for 1 h, it
was incubated with anti-rabbit IgG conjugated with HRP. The im-
munoadsorbed proteins were ¢nally detected with a chemilumines-
cence kit.
2.6. Expression and puri¢cation of MAp19 protein in Escherichia coli
cDNA encoding 170 amino acids of the N-terminal region (MAp19)
of MASP-2 except the signal peptide was ampli¢ed by polymerization
chain reaction (PCR) using the liver cDNA library as a template. The
PCR primers were designed to include BamHI and HindIII sites at the
5P- and 3P-end of the PCR product, respectively. The sequences of the
primers were as follows: 5P-CGGGATCCACCCCCTTGGGCCC-
GAAG-3P, 5P-GGAAGCTTGAGGCTCTGCTCTGAGCA-3P. The
PCR reactions were performed at the standard condition. The PCR
product was digested with restriction enzymes (BamHI and HindIII)
and subcloned into pET-21a expression vector. BL21 competent bac-
teria were transformed with this vector and cultured until the optical
density (OD) reached 1 at 600 nm. For induction of MAp19 in trans-
formed E. coli, IPTG was added to a ¢nal concentration of 0.5 mM to
this bacterial culture and bacterial cells were further incubated for 4 h
at 37‡C. After this induction of recombinant MAp19, bacterial cells
were centrifuged and the pellet was resuspended with a column bu¡er
containing 50 mM sodium phosphate, pH 7.5, 100 mM KCl, 0.1%
Tween 20, 10 WM phenylmethylsulfonyl £uoride (PMSF) and 20 mM
imidazole. After sonication, only soluble extracts were subjected to
the Ni-NTA column that was preequilibrated with this bu¡er. The
column was washed, and MAp19 was ¢nally eluted by adding 400
mM imidazole.
2.7. Assay of calcium oxalate monohydrate (COM) crystal growth
inhibition
Calcium oxalate crystal growth inhibition was measured as previ-
ously described with some modi¢cations [3]. This assay was performed
in a 1.5 ml microcentrifuge tube containing 0.67 ml of reaction bu¡er
(2 mM CaCl2 in barbituric acid, 133 mM NaCl, 0.03% acetic acid, pH
5.7), and 0.134 ml of calcium oxalate crystal slurry (1.5 mg/ml). 25 Wl
of protein samples was added to the tubes. Elution bu¡er containing
400 mM imidazole was used as a control. The reaction was started by
adding 0.67 ml of 0.4 mM sodium oxalate containing 40 nM
[14C]oxalic acid as a tracer in a 50 mM barbiturate-acetate bu¡er.
The assay solutions were incubated at 37‡C with shaking. After the
indicated period of incubation, the crystals were pelleted by centrifu-
gation for 30 s, and 100 Wl aliquots of supernatant were withdrawn.
These aliquots were counted in a liquid scintillation counter after
dissolving in 4 ml of scintillation cocktail (Wallac-Pharmacia).
3. Results
3.1. 19 kDa MAp19 was detected in human urine
To ¢nd an inhibitor of calcium oxalate crystallization from
human urine, we screened urine protein samples from patients
with renal cell carcinoma and normal adults. After partial
puri¢cation of urine by DEAE-cellulose ion exchange chro-
matography, the eluates were separated on 15% SDS-PAGE
and stained with Coomassie blue. The results showed that two
out of ¢ve urine protein samples obtained from patients with
renal cell carcinoma show protein bands in the region of 19
kDa, which was not detectable in the urine of normal subjects
(Fig. 1). In order to reveal the identity of this protein, we
attempted to determine the amino acid sequence of this pro-
tein. To do this, we cut out a 19 kDa protein band from the
15% SDS-PAGE gel after Coomassie blue staining, eluted
from the gel and sequenced using the Applied Biosystems
sequencer after in situ trypsin digestion. The results showed
that amino acid sequences of three peptides were identical to
the N-terminal region of the recently identi¢ed MAp19
[16,17]. The amino acid sequences of the three peptides,
with the positions of the three peptides in MAp19 in paren-
theses, are as follows: peptide 1, LASPGFPGEYANDQER
Fig. 1. SDS-PAGE analysis of partially puri¢ed MAp19 from urine.
The MAp19 protein mixtures were partially puri¢ed from urine
samples of ¢ve renal cell carcinoma patients (lanes 1^5) and two
normal adults (lanes 6,7) by DEAE-cellulose anion exchange chro-
matography. 100 Wg of these mixtures were subjected to 15% SDS-
PAGE and stained with Coomassie blue. The arrow indicates a pro-
tein of molecular mass approximately 19 kDa. M: protein molecular
weight marker.
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(29^45); peptide 2, WTLTAPPGYR (47^56); peptide 3,
SDYSNEKPFTGFEAF (119^133).
In order to determine the amount of MAp19 in urine, we
next raised antibody against MAp19 by immunizing a rabbit
with peptide synthesized based on the peptide 1 sequence, and
then puri¢ed by an antigen-conjugated a⁄nity column follow-
ing ammonium sulfate precipitation. Using this antibody, we
semiquanti¢ed the MAp19 amount in patients with renal cell
carcinoma and normal subjects. The results showed that it is
present in urine of both patients with renal cell carcinoma and
normal adults, although the amount of MAp19 was higher in
urine samples from patients with renal cell carcinoma than
normal adults (Fig. 2).
3.2. MAp19 is present in urine as a calcium-binding protein
MAp19 has common domain structures such as a C1r/C1s-
like domain and an EGF-like domain [16,17]. This EGF-like
domain in the C-terminal region is predicted to have a calci-
um-binding helix-loop-helix motif termed an EF-hand [22,23],
and it also has the key residues involved in the calcium-bind-
ing sites. To test whether MAp19 is a calcium-binding protein,
we treated urine dialysates with 50 mM EDTA for 24 h,
partially puri¢ed by DEAE-cellulose ion chromatography,
and analyzed by SDS-PAGE and by immunoblot. When
they were treated with EDTA before puri¢cation, two urine
samples showed increases in band intensity around the 19 kDa
region on SDS-PAGE analysis (Fig. 3A). However, all of the
urine samples pretreated with EDTA showed a signi¢cant
increase in MAp19 band intensity on immunoblot analysis
(Fig. 3B). Next, we examined whether it is present as an
aggregated oligomer like nephrocalcin. When we treated urine
samples with 50 mM EDTA for 24 h after partial puri¢cation,
there was no increase in MAp19 band intensity on immuno-
blot analysis (Fig. 3C). These results suggest that MAp19 is a
calcium-binding protein that exists as a monomeric form in
urine.
3.3. Recombinant MAp19 inhibits calcium oxalate crystal
growth in vitro
Although MAp19 was detected as part of the MBL-MASP
complex that activates the complement system, we speculated
that MAp19 in urine might have another function related to
its calcium-binding property. Therefore, we next investigated
whether this protein can inhibit calcium oxalate crystal
growth like other urinary proteins such as urinary bikunin/
urinary acidic protein/nephrocalcin [24^26], Tamm-Horsfall
Fig. 2. Immunoblot analysis of MAp19 in urine after partial puri¢-
cation. MAp19 partially puri¢ed from urine samples of ¢ve renal
cell carcinoma patients (lanes 1^5) and two normal adults (lanes
6,7) was semiquanti¢ed after separation on 15% SDS-PAGE by im-
munoblot using polyclonal anti-MAp19 antibody. In each lane, 10
Wg of protein was loaded.
Fig. 3. Increase in the amount of MAp19 with EDTA pretreatment.
The e¡ect of EDTA treatment of urine dialysate prior to DEAE-cel-
lulose chromatography on the recovery of MAp19 was examined by
SDS-PAGE (A) and immunoblot (B). The partially puri¢ed urine
proteins were also treated with EDTA and analyzed by immunoblot
(C). The urine samples without a MAp19 band on SDS-PAGE were
treated with (+) or without (3) 50 mM EDTA for 24 h at 4‡C.
Each two lanes are a pair of urine samples from the same person.
Fig. 4. Expression and puri¢cation of MAp19 in E. coli. MAp19
was overexpressed after 0.5 mM IPTG induction for 4 h, and it was
puri¢ed from transformed E. coli lysates using Ni-NTA a⁄nity
chromatography. Protein was analyzed by 15% SDS-PAGE (A),
and immunoblotted with anti-MAp19 antibody (B). Lane 1, soluble
fraction of cell lysate; lane 2, soluble fraction of cell lysate after
IPTG induction for 4 h; lane 3, MAp19 puri¢ed by Ni-NTA a⁄n-
ity chromatography.
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protein [27], and uropontin [28]. To do this work, we ¢rst
obtained cDNA of MAp19 by polymerase chain reaction
(PCR) using the liver cDNA library as a template, and sub-
cloned this PCR product into a prokaryotic expression vector,
pET-21a. After subcloning, we induced MAp19 in E. coli us-
ing 0.5 mM IPTG. Since MAp19 was fused with a 6UHis tag,
it was puri¢ed using Ni-NTA a⁄nity chromatography. This
puri¢cation method produces a single protein on SDS-PAGE
with a molecular mass of approximately 19 kDa as we ex-
pected (Fig. 4A). Immunoblot analysis con¢rmed that the
overexpressed protein is indeed MAp19 (Fig. 4B). Next, we
tested whether recombinant MAp19 has an inhibitory activity
on calcium oxalate crystal growth in vitro. It was not exposed
to EDTA for this assay. The result showed that MAp19 in-
hibits calcium oxalate crystal growth in a concentration-de-
pendent manner in vitro (Fig. 5).
4. Discussion
In this study, we ¢rst showed that MAp19 is excreted in
urine of patients with renal cell carcinoma and normal adults
although its amount is higher in urine of renal cell carcinoma
patients. We also showed for the ¢rst time that recombinant
MAp19 has an inhibitory activity on calcium oxalate crystal
growth in vitro. Since MAp19 is an alternatively spliced form
of MASP-2 which is a component of a complement system,
our ¢nding that MAp19 is excreted more in urine of renal cell
carcinoma patients than normal adults suggests complement
activation by the MBL-MASP-2/MAp19 complex in renal cell
carcinoma. MBL can not only kill exogenous microorganisms,
but also destroy mammalian cells with mannose-type oligo-
saccharides on their surfaces [29]. Consistent with this report,
Magyarlaki et al. detected tissue deposition of C1q, IgG and
C3 in renal cell carcinoma biopsies indicating that a comple-
ment system is activated in renal cell carcinoma. However,
they also showed that these renal cell carcinomas with com-
plement activation also express the membrane-bound comple-
ment regulatory factors that may inhibit complement-medi-
ated tumor cell lysis [30]. Thus, it is to be determined
whether this complement activation by the MBL-MASP-2/
MAp19 complex causes any signi¢cant damage to renal cell
carcinoma.
Pretreatment of urine dialysate with 50 mM EDTA in-
creased the recovery of MAp19, whereas the puri¢ed samples
did not give larger amounts of MAp19 even after treatment
with the same concentration of EDTA. These results suggest
that MAp19, unlike nephrocalcin, is present as a monomeric
form in the presence of calcium ion. Also, the reason why we
recovered more MAp19 with EDTA pretreatment seems to be
that it is bound more to DEAE-cellulose anion resin upon
removal of Ca2 ion from protein. In fact, MAp19 has a
domain rich in acidic amino acids (Asp and Glu) in its C-
terminal region, and these residues may provide an ideal elec-
trostatic environment for Ca2 binding. These properties of
urinary proteins seem to be responsible for the inhibitory
activity of calcium oxalate monohydrate growth [31].
It remains to be determined if MAp19 can inhibit other
stages of crystallization, since the formation of renal stones
requires nucleation, growth, aggregation of crystals, and crys-
tal attachment to renal epithelial cells. Actually, urinary pro-
teins inhibit more than one stage of this crystallization [24].
For example, Tamm-Horsfall protein inhibits growth and ag-
gregation without inhibition of nucleation, whereas nephro-
calcin has been found to inhibit all three stages of crystalliza-
tion [24]. Thus, we are currently investigating whether it can
inhibit other stages of crystallization.
In summary, we showed that MAp19 inhibits calcium ox-
alate crystal growth in vitro, suggesting that it plays a role as
an inhibitor of renal stone formation in urine.
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